Ascendis Pharma A/S reports results for the quarter ended in June - Earnings Summary

Ascendis Pharma A/S

05/09/2023 22:01

* Ascendis Pharma A/S  ASND.OQ  reported a quarterly
adjusted loss
of €2.16​​ per share for the quarter ended in June. The mean
expectation of ten analysts for the quarter was for a loss of
€2.59 per share.
    * Revenue rose 669.4% to €47.39 million from a year ago;
analysts
expected €37.35 million. 
    * Ascendis Pharma A/S's reported EPS for the quarter was a
loss of
€2.16​.
    * The mean earnings estimate of analysts had fallen by
about 2.4%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Ascendis Pharma A/S shares had risen by 10.1% this
quarter and
lost 19.5% so far this year.
    * The company reported a quarterly loss of €121.43 million.
    * Wall Street's median 12-month price target for Ascendis
Pharma
A/S is $146.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 10 "strong buy" or "buy," 4
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
September 5 at 09:01 p.m. UTC. ​All figures in euros unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2023      -2.59          -2.16          Beat
 Mar. 31 2023      -2.66          -1.98          Beat
 Dec. 31 2022      -2.56          -3.70          Missed
 Sep. 30 2022      -2.49          -3.03          Missed